Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma
Open Access
Abstract
Understanding the metabolic reprogramming of aggressive brain tumors has potential applications for therapeutics as well as imaging biomarkers. However, little is known about the nutrient requirements of isocitrate dehydrogenase 1 (IDH1) mutant gliomas. The IDH1 mutation involves the acquisition of a neomorphic enzymatic activity which generates D-2-hydroxyglutarate from α-ketoglutarate. In order to gain insight into the metabolism of these malignant brain tumors, we conducted metabolic profiling of the orthotopic tumor and the contralateral regions for the mouse model of IDH1 mutant glioma; as well as to examine the utilization of glucose and glutamine in supplying major metabolic pathways such as glycolysis and tricarboxylic acid (TCA). We also revealed that the main substrate of 2-hydroxyglutarate is glutamine in this model, and how this re-routing impairs its utilization in the TCA. Our 13C tracing analysis, along with hyperpolarized magnetic resonance experiments, revealed an active glycolytic pathway similar in both regions (tumor and contralateral) of the brain. Therefore, we describe the reprogramming of the central carbon metabolism associated with the IDH1 mutation in a genetically engineered mouse model which reflects the tumor biology encountered in glioma patients.Keywords
Funding Information
- National Institutes of Health (Intramural Program)
This publication has 44 references indexed in Scilit:
- Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging MicroscopyBiosensors, 2018
- Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma CellsCell Reports, 2018
- Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilitiesCancer & Metabolism, 2018
- Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous systemNeuro-Oncology, 2018
- Mutant IDH1 regulates the tumor-associated immune system in gliomasGenes & Development, 2017
- Understanding the Intersections between Metabolism and Cancer BiologyCell, 2017
- IDH mutations in cancer and progress toward development of targeted therapeuticsAnnals of Oncology, 2016
- Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse GliomaCell, 2016
- Abstract 33: Cancer-associated IDH1 mutations produce 2-hydroxyglutarateCancer Research, 2010
- IDH1 Mutations Are Early Events in the Development of Astrocytomas and OligodendrogliomasThe American Journal of Pathology, 2009